Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans

Molecular Metabolism

Volumn 3, Issue 6, 2014, Pages 676-680

  Wagner, Robert ^a,b,c   Hieronimus, Anja ^a,b,c   Lamprinou, Apostolia ^a,b,c   Heni, Martin ^a,b,c   Hatziagelaki, Erifili ^d   Ullrich, Susanne ^a,b,c   Stefan, Norbert ^a,b,c   Staiger, Harald ^a,b,c   Häring, Hans Ulrich ^a,b,c   Fritsche, Andreas ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

FFAR1; Free fatty acid receptor 1; G protein coupled receptor 40; GPR40; Insulin secretion; PPARG

Indexed keywords

FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; FEMALE; GENE INTERACTION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84906219758     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.07.001     Document Type: Article

References (26)

1. Brisson G.R., Malaisse-Lagae F., Malaisse W.J. The stimulus-secretion coupling of glucose-induced insulin release. VII. A proposed site of action for adenosine-3',5'-cyclic monophosphate. The Journal of Clinical Investigation 1972, 51:232-241. 10.1172/JCI106808.
2. Meglasson M.D., Matschinsky F.M. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes/Metabolism Reviews 1986, 2:163-214. 10.1002/dmr.5610020301.
3. Nolan C.J., Madiraju M.S.R., Delghingaro-Augusto V., Peyot M.-L., Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006, 55(Suppl. 2):S16-S23. 10.2337/diabetes.
4. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176. 10.1038/nature01478.
5. Boden G., Chen X., Rosner J., Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995, 44:1239-1242. 10.2337/diab.44.10.1239.
6. Kashyap S., Belfort R., Gastaldelli A., Pratipanawatr T., Berria R., Pratipanawatr W., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003, 52:2461-2474. 10.2337/diabetes.52.10.2461.
7. Prentki M., Matschinsky F.M., Madiraju S.R.M. Metabolic signaling in fuel-induced insulin secretion. Cell Metabolism 2013, 18:162-185. 10.1016/j.cmet.2013.05.018.
8. Poitout V., Lin D.C.-H. Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discovery Today 2013, 18:1301-1308. 10.1016/j.drudis.2013.09.003.
9. Wagner R., Kaiser G., Gerst F., Christiansen E., Due-Hansen M.E., Grundmann M., et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 2013, 62:2106-2111. 10.2337/db12-1249.
10. Kim H.-S., Hwang Y.-C., Koo S.-H., Park K.S., Lee M.-S., Kim K.-W., et al. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells. PLoS ONE 2013, 8:e50128. 10.1371/journal.pone.0050128.
11. Stefan N., Fritsche A., Häring H., Stumvoll M. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene. Diabetes 2001, 50:1143-1148. 10.2337/diabetes.50.5.1143.
12. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
13. Seltzer H.S., Allen E.W., Herron A.L., Brennan M.T. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. The Journal of Clinical Investigation 1967, 46:323-335. 10.1172/JCI105534.
14. Albareda M., Rodríguez-Espinosa J., Murugo M., de Leiva A., Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000, 43:1507-1511. 10.1007/s001250051561.
15. Hanson R.L., Pratley R.E., Bogardus C., Narayan K.M.V., Roumain J.M.L., Imperatore G., et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. The American Journal of Epidemiology 2000, 151:190-198.
16. Deeb S.S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998, 20:284-287. 10.1038/3099.
17. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000, 26:76-80. 10.1038/79216.
18. Stumvoll M., Häring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002, 51:2341-2347.
19. Kalis M., Levéen P., Lyssenko V., Almgren P., Groop L., Cilio C.M. Variants in the FFAR1 gene are associated with beta cell function. PLoS ONE 2007, 2:e1090. 10.1371/journal.pone.0001090.
20. Gupta D., Kono T., Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2010, 12:1036-1047. 10.1111/j.1463-1326.2010.01299.x.
21. Stumvoll M., Wahl H.G., Loblein K., Becker R., Machicao F., Jacob S., et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001, 50:876-881. 10.2337/diabetes.50.4.876.
22. Stumvoll M., Häring H. Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2?. Diabetologia 2002, 45:152-153. 10.1007/s001250200018.
23. Vangipurapu J., Stančáková A., Pihlajamäki J., Kuulasmaa T.M., Kuulasmaa T., Paananen J., et al. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. Diabetologia 2011, 54:563-571. 10.1007/s00125-010-1977-4.
24. Ichimura A., Hirasawa A., Hara T., Tsujimoto G. Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins & Other Lipid Mediators 2009, 89:82-88. 10.1016/j.prostaglandins.2009.05.003.
25. Lead GPR40 agonist bites the dust. Nature Review Drug Discovery 2014, 13:91. 10.1038/nrd4246.
26. Wagner R., Staiger H., Ullrich S., Stefan N., Fritsche A., Häring H.-U. Untangling the interplay of genetic and metabolic influences on beta-cell function: examples of potential therapeutic implications involving TCF7L2 and FFAR1. Molecular Metabolism 2014, 3:261-267. 10.1016/j.molmet.2014.01.001.